What is Neuronoff?
Neuronoff is at the forefront of non-pharmacological pain relief, offering its innovative Injectrode® Platform. This technology provides chronic pain patients with an alternative to drugs and invasive procedures. The platform's core innovation lies in its simple, needle-based placement, which establishes a low impedance path for electrical signals to effectively alleviate pain. Neuronoff's mission is to replace the cycle of repeat drug injections with a more accessible and sustainable pain management solution.
How much funding has Neuronoff raised?
Neuronoff has raised a total of $12.2M across 3 funding rounds:
Multiple Rounds
$12.2M
Grant (2025): $3.2M with participation from National Institutes of Health
Other Financing Round (2025): $4.5M, investors not publicly disclosed
Other Financing Round (2025): $4.5M, investors not publicly disclosed
Key Investors in Neuronoff
National Institutes of Health
The National Institutes of Health (NIH) is a primary agency of the U.S. Department of Health and Human Services, responsible for biomedical and health-related research.
What's next for Neuronoff?
With the infusion of major strategic investment, Neuronoff is poised for accelerated growth and market penetration. The company's focus on drug-free, minimally invasive pain relief aligns with a growing demand for alternative therapeutic approaches. This capital injection will likely fuel further research and development, expand clinical trials, and bolster commercialization efforts to bring the Injectrode® Platform to a wider patient population. The company's trajectory suggests a strong potential for market leadership in the chronic pain sector.
See full Neuronoff company page
